Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gsk2256294. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 known ✓ | P34913 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk2256294 SCHEMBL2677673 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL2677667 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL29667411 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL29557121 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| Gsk2256294 SCHEMBL30216212 | 1.00 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677883 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677886 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2677878 | 0.89 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2678417 | 0.88 | EPHX2 (0.79) | EPHX2CYP2C9CYP3A4CYP2D6 | |
| SCHEMBL2676508 | 0.88 | EPHX2 (0.79) | EPHX2CYP2C9CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | claimed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | claimed |
| US-20210228539-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2021-07-29 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-05-02 | — | — | US | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| EP-2214487-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-11-27 | — | — | EP | claimed |
| US-8173805-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2012-05-08 | — | — | US | claimed |
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | GlaxoSmithKline, LLC | 2010-09-30 | — | — | US | claimed |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| EP-2214487-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | disclosed |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-15 | — | — | US | disclosed |
| EP-2214487-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009049157-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249137-A1 | Novel sEH Inhibitors and Their Use | NCEH1, CTH, EPHX1 | EPHX2 8/4885CYP2C9 377/4885CYP3A4 211/4885 |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, ALDH1A2, EPHX2 | EPHX2 3/4885CYP2C9 3672/4885CYP3A4 3461/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885CYP2C9 4118/4885CYP3A4 3371/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 1783/4885CYP3A4 2907/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885CYP2C9 591/4885CYP3A4 542/4885 |
| US-12357598-B2 | Treatment of neurodevelopmental disorders | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885CYP2C9 4118/4885CYP3A4 3371/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885CYP2C9 1319/4885CYP3A4 2105/4885 |
| US-20100210656-A1 | NOVEL sEH INHIBITORS AND THEIR USE | NCEH1, EPHX1, FAH | EPHX2 4/4885CYP2C9 140/4885CYP3A4 129/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | EPHX2 534/4885CYP2C9 4709/4885CYP3A4 4693/4885 |
| US-20210228539-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, NCEH1, ALDH1A2 | EPHX2 4/4885CYP2C9 3876/4885CYP3A4 3941/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885CYP2C9 1783/4885CYP3A4 2907/4885 |
| US-20190125696-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885CYP2C9 591/4885CYP3A4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.